

Guideline Template

- Link to AASLD guideline (Wiley)

<https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.29800>

- CME? NO

Issue HBV Special Issue July 2018

Guideline title: **Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance**

Publication date: First published: 05 February 2018

Revision? YES update to practice guideline published in 2015

Guest Editor: Tram Tran

Guideline Author: Norah A. Terrault, Anna S.F. Lok, Brian J. McMahon, Kyong-Mi Chang, Jessica P. Hwang, Maureen M. Jonas, Robert S. Brown Jr., Natalie H. Bzowej, John B. Wong

Questions : EASL interview

1. What is different in the 2018 update compared to the previous publication in 2012?
2. How do you advise a clinician to use the NAFLD guideline in clinical practice?
3. Significant efforts in diagnostics and therapeutics are occurring in NAFLD. Do you see this as having an impact on the frequency guideline updates?. When do you see a dynamic platform (such as that used for the HCV guidance document) as being important for NAFLD?

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/cld.728](https://doi.org/10.1002/cld.728)

This article is protected by copyright. All rights reserved

EIC Blurb:

In February 2018 AASLD published an update to the practice guideline on the **prevention, diagnosis, and treatment of chronic hepatitis B (CHB)**. [LINK] In contrast the prior version, this *guidance* document was developed by consensus of an expert panel, without formal systematic review or use of the Grading of Recommendations Assessment, Development, and Evaluation system. The 2018 guidance is based upon the following: (1) formal review and analysis of published literature on the topics; (2) World Health Organization guidance on prevention, care, and treatment of CHB; and (3) the authors' experience in acute hepatitis B and CHB. This guidance is intended for use by health care providers, this guidance identifies preferred approaches to the diagnostic, therapeutic, and preventive aspects of care for patients with CHB. As with clinical practice guidelines, it provides general guidance to optimize the care of the majority of patients and should not replace clinical judgement for a unique patient. This guidance does not seek to dictate a "one size fits all" approach for the management of CHB. Clinical considerations may justify a course of action that differs from this guidance.

The 2018 HBV guideline is intended to complement the previous editions. The update addresses five major areas of change. The new version (1) includes updates on treatment since the 2016 HBV guidelines (notably the use of tenofovir alafenamide) and guidance on (2) screening, counseling, and prevention; (3) specialized virological and serological tests; (4) monitoring of untreated patients; and (5) treatment of hepatitis B in special populations, including persons with viral coinfections, acute hepatitis B, recipients of immunosuppressive therapy, and transplant recipients.

Please listen to Dr Norah Terrault discuss [Modify after interview]